News

TriLink CleanCap® mRNA capping technology is now accessible to Fujifilm customers for non-commercial use TOKYO, February 5, 2024 – TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, and FUJIFILM Toyama Chemical, a Japanese provider of synthetic mRNA contract development and manufacturing services, have entered into a non-exclusive License and Supply Agreement for TriLink’s CleanCap® mRNA capping technology. Aligned to the terms of the agreement, TriLink® will supply its proprietary CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG and CleanCap® AU cap analogs for use in Fujifilm’s mRNA development and manufacturing services in Japan, from pre-clinical through Phase III programs. This agreement aligns with TriLink’s objective to enable greater access to CleanCap® mRNA capping technologies. CleanCap® technology produces an optimal Cap1 structure with over 95% efficiency, creating a one-pot solution that streamlines production processes when compared to other capping methods. “Our novel

RESEARCH TRIANGLE PARK, North Carolina, June 1, 2023  – FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies today announced that it will showcase its bio CDMO expertise and capabilities at the  2023 BIO International Convention (BIO), booth #865, held June 5 – 8, 2023 at the Boston Convention & Exhibition Center in Boston. BIO is the largest annual event for the biotechnology and pharma industry attracting over 14,000 leaders and representatives for a week of partnering, showcasing the breadth and depth of industry innovations and networking.    This year FUJIFILM Diosynth Biotechnologies will leverage its expertise across multiple modalities to host five in-booth scientific and educational sessions led by its leaders across its global network. These sessions will cover a range of topics and the schedule is as follows:     Monday, June 5 2:00 PM EDT Advancing Tomorrow’s Protein

Cambridge, Mass. — June 1, 2023 — Fujifilm Life Sciences, a broad portfolio of Fujifilm Group operations offering products, services and comprehensive solutions that span support for all stages of therapeutic development from discovery through to commercialization, today announced that it will showcase its offerings across the therapeutics development process at BIO 2023 (June 5-8) to be held at the Boston Convention and Exhibition Center in Massachusetts, USA. “Fujifilm Life Sciences is proud to join BIO 2023 where we will showcase our group company solutions and explore new partnerships with today’s leading research organizations and biotech companies. Our business portfolio now includes cell culture solutions, research tools such as reagents, investigational drug development, drug delivery solutions, cell therapy development, quality control testing solutions, as well as Bio-CDMO. Through our comprehensive offering, we are uniquely positioned to support and accelerate bringing new therapies to patients in need,” said Yutaka Yamaguchi, corporate vice

MADISON, Wis., June 1, 2023 – FUJIFILM Cellular Dynamics, a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) today announces the global commercial launch of its human iPSC-derived iCell® Blood-Brain Barrier Isogenic Kit for scientists engaged in neuroscience research and drug discovery for neuroactive drugs. The first-of-its-kind kit models the human blood-brain barrier and can advance drug discovery, drug development and medical research for central nervous system (CNS) disorders. The iCell Blood-Brain Barrier Isogenic Kit is an off-the-shelf, ready to use, human iPSC-derived cell model that has barrier integrity and functionality consistent with in vivo physiological properties. The kit consists of human iPSC-derived iCell Brain Microvascular Endothelial Cells, iCell Pericytes, and iCell Astrocytes, as well as the critical culture media, which was jointly optimized through FUJIFILM Irvine Scientific Inc.’s media optimization program and is manufactured by FUJIFILM Irvine Scientific, Inc., and protocols necessary to provide a

Chemically defined, BalanCD HEK293 Viral Feed enhances viral vector production for gene therapy applications and viral vector-based vaccines SANTA ANA, Calif., January 10, 2023 — FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, today announced the launch of its BalanCD HEK293 Viral Feed. The chemically defined, nutrient-based HEK293-specific feed medium is designed to boost adeno-associated viral vector (AAV) production for gene therapy applications and viral vector-based vaccines. Numerous gene therapies have received FDA approval and as more viral vector-based vaccines and gene therapies move into commercialization, the demand for large-scale, efficient viral vector manufacturing is increasing. For manufacturers, it is imperative to boost viral vector production to meet supply demands for vaccine and gene therapy manufacture. BalanCD HEK293 Viral Feed is optimized to deliver high titers and improve viral packaging efficiency by

MADISON, WIS., January 5, 2023 — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases. Under the agreement, Novo Nordisk will have a non-exclusive license to use the iPSC cell lines for research and development purposes, and to utilize GMP-grade cell lines for clinical and commercial manufacture and commercialization of iPSC-derived cell therapies. Terms of the agreement were not disclosed. “FUJIFILM Cellular Dynamics is a global leader in the development and manufacturing of GMP-grade iPSCs for cell therapy applications. Our goal is to drive the iPSC field forward by building strategic partnerships,” said Tomoyuki Hasegawa, chief executive officer, FUJIFILM Cellular

Investment will Accelerate Development of New High-Content Screening Assay Services Using Differentiated iPSCs TOKYO, December 13, 2022 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces its investment in PhenoVista Biosciences (PhenoVista), a contract research organization (CRO) and leading provider of both custom and off-the-shelf imaging-based assay services based in San Diego, CA. Fujifilm and PhenoVista will accelerate the development of new high-content screening (HCS) assay services using FUJIFILM iCell® differentiated induced pluripotent stem cells (iPSCs) and PhenoVista’s cutting-edge imaging technologies. This investment is from the Life Sciences Corporate Venture Capital (LS-CVC) strategic investment fund. This investment builds upon the existing strategic alliance between FUJIFILM Corporation subsidiary, FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human iPSCs, and PhenoVista. FUJIFILM Cellular Dynamics aims to further expand its drug-discovery business through this alliance initiated in November 2021 by collaboratively developing high-content, imaging-based assays using human

TOKYO, November 22, 2022 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will be operated by FUJIFILM Irvine Scientific, Inc., a subsidiary of FUJIFILM Corporation, and a world leader in the development and manufacture of advanced cell culture solutions for life science research, bioproduction, cell therapy manufacturing, and medical applications. The new facility is planned to ensure that FUJIFILM Irvine Scientific can meet increasing market demands for high quality cell culture media solutions. The state-of-the-art manufacturing facility will be over 250,000 sq. feet and located across 64 acres in RTP. The site will support cGMP manufacturing of animal component-free, dry powder, and liquid media, adding additional production capacity for FUJIFILM Irvine Scientific of 800,000 Kg/year for dry powder, 3,300,000 L/year for liquid, and

MADISON, Wis., September 15, 2022 — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announces the appointment of Ilyas Singeç, M.D., as chief scientific officer effective September 12. In this newly created strategic role, Dr. Singeç will define the Company’s future iPSC technological pipeline. In his role as part of the Company’s executive leadership team, he will also help drive business strategy with the goal of transforming scientific research and healthcare by using iPSC technologies.  “We are thrilled to welcome Dr. Singeç to the FUJIFILM Cellular Dynamics family,” said Tomoyuki Hasegawa, chief executive officer, FUJIFILM Cellular Dynamics, Inc. “Dr. Singeç brings over 20 years of experience in cell and molecular biology, and extensive stem cell expertise, which will be instrumental as FUJIFILM Cellular Dynamics expands our application of leading-edge iPSC technologies to continue innovating in this field.” Prior to joining